Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three trials
Entrectinib shrank tumours in more than three quarters of patients with ROS1-positive lung cancer and, unlike crizotinib, controlled brain metastases in most patients who had them, earning approval as a first-line option.
Overview
Integrated analysis of 53 ROS1 inhibitor-naive patients with ROS1 fusion-positive non-small-cell lung cancer from the ALKA-372-001, STARTRK-1 and STARTRK-2 trials treated with entrectinib.
Objective response was 77 percent with median duration of response 24.6 months and median progression-free survival 19.0 months; intracranial response was 55 percent in patients with brain metastases.
- Objective response 77 percent; median progression-free survival 19.0 months.
- Intracranial response 55 percent.
Entrectinib is a first-line ROS1 inhibitor with brain activity, preferred over crizotinib when brain metastases are present, though repotrectinib and taletrectinib now offer longer control.
- Single-arm pooled analysis; does not cover the G2032R resistance mutation.
Similar pages
not linked directly; found by shared links- Key paperEntrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials
Shares Entrectinib, The Lancet Oncology.
- TrialA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Shares Entrectinib, ROS1-positive non-small-cell lung cancer.
- TrialBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme
Shares Entrectinib, ROS1-positive non-small-cell lung cancer.
- TargetROS1
Shares Entrectinib, ROS1-positive non-small-cell lung cancer.
- TargetNTRK
Shares Entrectinib, ROS1-positive non-small-cell lung cancer.